Format

Send to

Choose Destination
J Surg Oncol. 2016 Dec;114(7):838-847. doi: 10.1002/jso.24409. Epub 2016 Aug 28.

Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity.

Author information

1
Department of Surgery, University of California San Francisco, San Francisco, California.
2
Department of Pathology, University of California San Francisco, San Francisco, California.
3
Division of Hematology and Oncology, University of California San Francisco, San Francisco, California.
4
Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
5
Department of Surgery, University of California San Francisco, San Francisco, California. david.jablons@ucsf.edu.

Abstract

BACKGROUND:

There is a clear survival benefit to neoadjuvant chemoradiation prior to esophagectomy for patients with stages II-III esophageal cancer. A minimally invasive esophagectomy approach may decrease morbidity but is more challenging in a previously radiated field and therefore patients who undergo neoadjuvant chemoradiation may experience more postoperative complications.

METHODS:

A prospective database of all esophageal cancer patients who underwent attempted hybrid minimally invasive Ivor Lewis esophagectomy was maintained between 2006 and 2015. The clinical characteristics, neoadjuvant treatments, perioperative complications, and survival outcomes were reviewed.

RESULTS:

Overall 30- and 90-day mortality rates were 0.8% (1/131) and 2.3% (3/131), respectively. The majority of patients 58% (76/131) underwent induction treatment without significant adverse impact on mortality, major complications, or hospital stay. Overall survival at 1, 3, and 5 years was 85.9%, 65.3%, and 53.9%. Five-year survival by pathologic stage was stage I 68.9%, stage II 54.0%, and stage III 29.6%.

CONCLUSIONS:

The hybrid minimally invasive Ivor Lewis esophagectomy approach results in low perioperative morbidity and mortality and is well tolerated after neoadjuvant chemoradiation. Good long-term overall survival rates likely resulted from combined concurrent neoadjuvant chemoradiation in the majority of patients, which did not impact the ability to safely perform the operation or postoperative complications rates. J. Surg. Oncol. 2016;114:838-847. © 2016 2016 Wiley Periodicals, Inc.

KEYWORDS:

complete pathologic response; esophageal cancer long-term survival; esophagectomy complications; esophagectomy mortality; neoadjuvant chemoradiation

PMID:
27569043
DOI:
10.1002/jso.24409
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center